Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 31 for:    ptc124

Effects of Rifampin on the Pharmacokinetics of Ataluren

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02409004
Recruitment Status : Completed
First Posted : April 6, 2015
Last Update Posted : December 22, 2017
Sponsor:
Information provided by (Responsible Party):
PTC Therapeutics

Brief Summary:
This will be a single centre, Phase I, open-label, one cohort, one dose level, fixed-sequence, drug interaction study in healthy volunteers. The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Ataluren Drug: Rifampin Phase 1

Detailed Description:

A total of 15 healthy, adult, male non-smokers, were included in this study. Subjects were administered ataluren on Day 1 followed by rifampin from Days 3 to12, and again ataluren on Day 11. On Day 11, ataluren was administered before rifampin administration.

Prior to entering the trial, subjects had a screening visit to establish eligibility within 28 days before study drug administration. Subjects were confined from at least10 hours before the first ataluren dosing on Day 1 until approximately 50 hours postdose(Day 3). Thereafter, subjects came back every morning from Days 4 to 10 for rifampin dosing. Then, subjects reported to the clinical site at least 10 hours before ataluren dosing on Day 11 (evening of Day 10) and remained in the clinical site until after 50 hours post-Day 11 ataluren dose (Day 13).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study Assessing the Effects of Rifampin on the Pharmacokinetics of Ataluren in Healthy Subjects
Study Start Date : February 2015
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Rifampin

Arm Intervention/treatment
Experimental: Ataluren
Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
Drug: Ataluren
Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
Other Name: Ataluren(PTC124)

Drug: Rifampin
Capsule 2x3oo mg Oral
Other Name: Rifadin®




Primary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) [ Time Frame: 12 days ]
    The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.

  2. Maximum plasma concentration (Cmax) [ Time Frame: 12 days ]
    The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.


Secondary Outcome Measures :
  1. Safety as measured by adverse events, laboratory abnormalities, vital signs, and electrocardiogram parameters [ Time Frame: 12 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male, non-smoker (no use of tobacco products within two years prior to screening), ≥18 and ≤55 years of age, with Body Mass Index (BMI) >20.0 and <30.0 kg/m2 and body weight ≥50.0 kg.
  2. Healthy as defined by:

    1. the absence of clinically significant illness and surgery within four weeks prior to dosing. Subjects vomiting within 24 hours pre-first dose of ataluren will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the QI;
    2. the absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease;
    3. the absence of any known nonsense mutation-mediated disease including Duchenne Muscular Dystrophy.
  3. Capable of consent.
  4. Willing to take off dentures at dosing.
  5. Consent to perform genotyping for UGT1A9

Exclusion Criteria:

  1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
  2. Positive urine drug screen or urine cotinine test at screening.
  3. History of allergic reactions to ataluren, rifampin, or other related drugs.
  4. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to the first study drug administration.
  5. Any reason which, in the opinion of the QI, would prevent the subject from participating in the study.
  6. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  7. History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
  8. History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within three months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], and crack) within one year prior to screening.
  9. Participation in a clinical trial involving the administration of an investigational or marketed drug within 30 days (90 days for biologics) prior to the first dosing or concomitant participation in an investigational study involving no drug administration.
  10. Use of medication other than topical products without significant systemic absorption:

    1. prescription medication within 14 days prior to the first dosing;
    2. over-the-counter products including natural health products (eg, food supplements and herbal supplements) within seven days prior to the first ataluren dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
    3. a depot injection or an implant of any drug within three months prior to the first dosing.
  11. Donation of plasma within seven days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
  12. Hemoglobin <128 g/L and hematocrit <0.37 L/L at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02409004


Locations
Layout table for location information
Canada
Inventiv
Quebec, Canada, G1P 0A2
Sponsors and Collaborators
PTC Therapeutics
Investigators
Layout table for investigator information
Study Director: Oscar Laskin, MD PTC Therapeutics

Layout table for additonal information
Responsible Party: PTC Therapeutics
ClinicalTrials.gov Identifier: NCT02409004     History of Changes
Other Study ID Numbers: PTC124-GD-026-HV
First Posted: April 6, 2015    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by PTC Therapeutics:
Drug-drug interaction

Additional relevant MeSH terms:
Layout table for MeSH terms
Rifampin
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers